Wu, Jia http://orcid.org/0000-0001-8392-8338
Li, Chao http://orcid.org/0000-0002-0734-0011
Gensheimer, Michael
Padda, Sukhmani
Kato, Fumi
Shirato, Hiroki
Wei, Yiran
Schönlieb, Carola-Bibiane
Price, Stephen John
Jaffray, David
Heymach, John
Neal, Joel W.
Loo, Billy W. Jr
Wakelee, Heather
Diehn, Maximilian
Li, Ruijiang
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K99 CA218667, R00 CA218667)
University of Texas MD Anderson Cancer Center Lung Moon Shot Program
Article History
Received: 28 January 2021
Accepted: 24 June 2021
First Online: 9 August 2021
Competing interests
: J.H. reports fees for advisory committees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum and Takeda, research support from AstraZeneca, GlaxoSmithKline, Spectrum, and royalties and licensing fees from Spectrum. M.D. reports research funding from AstraZeneca, Varian Medical Systems and Illumina, ownership interest in CiberMed and Foresight Diagnostics, patent filings related to cancer biomarkers, and paid consultancy from Roche, Genentech, AstraZeneca, Novartis, Boehringer Ingelheim, Gritstone Oncology, RefleXion and BioNTech.